Sepracor Allegra Royalties Reduced in Patent Settlement With Hoechst
Executive Summary
Sepracor's U.S. royalties from Allegra will be lower under an amendment to the company's existing arrangement with Hoechst Marion Roussel. As a settlement of all patent issues involving the non-sedating antihistamine, Hoechst received the Sepracor U.S. patent properties related to fexofenadine.